Susquehanna Fundamental Investments LLC Invests $680,000 in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Susquehanna Fundamental Investments LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 80,319 shares of the specialty pharmaceutical company's stock, valued at approximately $680,000. Susquehanna Fundamental Investments LLC owned 0.16% of KalVista Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of KALV. SG Americas Securities LLC raised its holdings in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after purchasing an additional 1,319 shares during the last quarter. Legal & General Group Plc raised its stake in shares of KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after buying an additional 1,670 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after buying an additional 2,043 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after acquiring an additional 2,588 shares during the period.

Analysts Set New Price Targets

Several research firms have commented on KALV. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. JMP Securities started coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target for the company. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Finally, TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $24.83.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,669 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the sale, the chief executive officer now directly owns 287,811 shares in the company, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Venrock Healthcare Capital Par purchased 73,649 shares of the company's stock in a transaction on Friday, February 7th. The stock was acquired at an average price of $9.29 per share, with a total value of $684,199.21. Following the purchase, the insider now owns 5,086,445 shares of the company's stock, valued at approximately $47,253,074.05. This represents a 1.47 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 202,786 shares of company stock valued at $1,880,511 and have sold 17,292 shares valued at $184,625. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock traded down $0.18 on Wednesday, reaching $12.32. The company had a trading volume of 152,012 shares, compared to its average volume of 411,785. The firm's 50 day moving average price is $11.99 and its two-hundred day moving average price is $10.42. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50. The firm has a market cap of $612.25 million, a PE ratio of -3.39 and a beta of 0.05.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).